Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to use its Matrix-M adjuvant in vaccine products for up to two infectious ...
Sweeping U.S. policy changes under Health Secretary Robert F. Kennedy Jr. are having a chilling effect on vaccine makers as ...
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company ...
Shares of US biotech Novavax were up 9% at $8.72 by midday on Tuesday, after it revealed it has entered into a license ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for ...
Novavax NVAX incurred a loss of 62 cents per share in the third quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of $1.08 per share. In the year-ago quarter, the company ...
GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Thursday reported a loss of $202.4 million in its third quarter. On a per-share basis, the Gaithersburg, Maryland-based company ...
(RTTNews) - Novavax (NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid to Sanofi (SNY), enabling Sanofi to take full responsibility for ...
GAITHERSBURG, Md., Nov. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid™ to Sanofi, enabling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results